benefix 500iu powder and solvent for solution for injection
wyeth farma s.a. - nonacog alfa - powder and solvent for solution for injection - 500iu
benefix 1000iu powder and solvent for solution for injection
wyeth farma s.a. - nonacog alfa - powder and solvent for solution for injection - 1000iu
benefix 2000iu powder and solvent for solution for injection
wyeth farma s.a. - nonacog alfa - powder and solvent for solution for injection - 2000iu
idelvion- coagulation factor ix recombinant human kit
csl behring lengnau ag - albutrepenonacog alfa (unii: a57kx1vl5p) (albutrepenonacog alfa - unii:a57kx1vl5p) - albutrepenonacog alfa 250 [iu] in 2.5 ml - idelvion® , coagulation factor ix (recombinant), albumin fusion protein (rix-fp), a recombinant dna-derived coagulation factor ix concentrate, is indicated in children and adults with hemophilia b (congenital factor ix deficiency) for: - on-demand treatment and control of bleeding episodes - perioperative management of bleeding - routine prophylaxis to reduce the frequency of bleeding episodes limitations of use: idelvion is not indicated for immune tolerance induction in patients with hemophilia b. idelvion is contraindicated in patients who have had life-threatening hypersensitivity reactions to idelvion, or its components, including hamster proteins [see warnings and precautions (5.1)] . risk summary there are no data with idelvion use in pregnant women to inform on drug-associated risk. animal reproduction studies have not been conducted using idelvion. it is not known whether idelvion can cause fetal harm or affect reproduction capacity when administered to a pregnant woman. in the u.s. general populati
alprolix (coagulation factor ix- recombinant, fc fusion protein kit
biogen inc. - eftrenonacog alfa (unii: 02e00t2qde) (eftrenonacog alfa - unii:02e00t2qde) - eftrenonacog alfa 500 [iu] in 5 ml - alprolix, coagulation factor ix (recombinant), fc fusion protein, is a recombinant dna derived, coagulation factor ix concentrate indicated in adults and children with hemophilia b (congenital factor ix deficiency) for: - on demand treatment and control of bleeding episodes, - perioperative management of bleeding, - routine prophylaxis to reduce the frequency of bleeding episodes. limitation of use alprolix is not indicated for induction of immune tolerance in patients with hemophilia b [see warnings and precautions (5.3)]. alprolix is contraindicated in individuals who have a known history of hypersensitivity reactions, including anaphylaxis, to the product or its excipients (sucrose, mannitol, sodium chloride, l-histidine and polysorbate 20) . . pregnancy category c animal reproductive studies have not been conducted with alprolix. it is also not known whether alprolix can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. alprolix should be given to a pregnant woma
alprolix (coagulation factor ix- recombinant, fc fusion protein kit
bioverativ therapeutics inc. - eftrenonacog alfa (unii: 02e00t2qde) (eftrenonacog alfa - unii:02e00t2qde) - eftrenonacog alfa 500 [iu] in 5 ml - alprolix, coagulation factor ix (recombinant), fc fusion protein, is a recombinant dna derived coagulation factor ix concentrate indicated in adults and children with hemophilia b (congenital factor ix deficiency) for: - on-demand treatment and control of bleeding episodes, - perioperative management of bleeding, - routine prophylaxis to reduce the frequency of bleeding episodes. limitation of use: alprolix is not indicated for induction of immune tolerance in patients with hemophilia b. alprolix is contraindicated in individuals who have a known history of hypersensitivity reactions, including anaphylaxis, to the product or its excipients (sucrose, mannitol, sodium chloride, l-histidine and polysorbate 20). risk summary there are no studies of alprolix use in pregnant women to inform a drug-associated risk. the background risk of major birth defects and miscarriage for the indicated population is unknown; however, the background risk in the u.s. general population of major birth defects is 2%–4% and of misca
benefix 250 ui polvo y disolvente para solucion inyectable
pfizer europe ma eeig. - nonacog alfa (factor ix recombinante) - nonacog alfa (factor ix recombinante)....250 ui/ vial / cloruro de sodio....0,234%
benefix 500 ui polvo disolvente para solucion inyectable
pfizer europe ma eeig - nonacog alfa (factor ix recombinante) - nonacog alfa (factor ix recombinante)....500 mg / cloruro de sodio....0,234%
alprolix
pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 4000 [iu]; - powder for infusion - 4000 iu - active: eftrenonacog alfa 4000 [iu] excipient: histidine hydrochloric acid mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)
benefix 1000 iu powder and solvent for solution for injection
nonacog alfa - powder and solvent for solution for injection - 1000 iu - nonacog alfa